Patients newly diagnosed with breast cancer face a series of complex decisions regarding locoregional and systemic treatment. Currently many of these decisions do not meet the definition of a high quality decision,defined as one that is both informed (i.e., based on an accurate understanding of the treatment risks and benefits) and preference-concordant (i.e., consistent with the patients'underlying preferences). Moreover, the introduction of evaluative tests has made these decisions more complicated for many patients. There is a need to improve the quality of locoregional and systemic treatment decisions for breast cancer patients, and to help patients understand the role of evaluative tests in this decision process. Ensuring patients can deliberate effectively about these decisions, assert their views and communicate with their clinicians is likely to improve their overall decision preparedness and satisfaction. Project 3 will focus on the third pillar of individualized care by evaluating the impact of an innovative decision tool on locoregional and systemic therapy decision making for newly diagnosed breast cancer patients. The innovative online decision tool has been developed and tested over the past two years by the CanSORT team (R21 CA129859). Pilot data suggests that this tool has a positive impact on patient knowledge and decision outcomes. The goal of project 3 is to evaluate the impact of this tool, after it is enhanced in collaboration with our Communication and Dissemination Core, on the quality of decision making for locoregional and systemic breast cancer treatment decision making. We will conduct a randomized controlled trial (RCT) of 444 newly diagnosed patients with invasive early stage breast cancer, seen by 28-30 surgeons in two SEER catchment areas. Patients will be randomized to view our comprehensive decision tool or a

Public Health Relevance

Breast cancer patients make many complex decisions from locoregional through systemic treatment. Ensuring these decisions are high quality is a priority. Project 3 will deploy and evaluate an innovative decision tool designed to improve locoregional and systemic breast cancer treatment decision making. The results can be translated into efforts to improve individualized decicision making for future patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Wallner, Lauren P; Li, Yun; McLeod, M Chandler et al. (2017) Decision-support networks of women newly diagnosed with breast cancer. Cancer 123:3895-3903
Taylor, Carolyn; Correa, Candace; Duane, Frances K et al. (2017) Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol 35:1641-1649
Katz, Steven J; Wallner, Lauren P; Abrahamse, Paul H et al. (2017) Treatment experiences of Latinas after diagnosis of breast cancer. Cancer 123:3022-3030
Li, Yun; Kurian, Allison W; Bondarenko, Irina et al. (2017) The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Breast Cancer Res Treat 161:587-595
Hawley, Sarah T; Morris, Arden M (2017) Cultural challenges to engaging patients in shared decision making. Patient Educ Couns 100:18-24
Kurian, Allison W; Griffith, Kent A; Hamilton, Ann S et al. (2017) Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . JAMA 317:531-534
Katz, Steven J; Hawley, Sarah T; Bondarenko, Irina et al. (2017) Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Breast Cancer Res Treat 165:751-756
Hawley, Sarah T; Janz, Nancy K; Griffith, Kent A et al. (2017) Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Res Treat 161:557-565
Jagsi, Reshma; Hawley, Sarah T; Griffith, Kent A et al. (2017) Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. JAMA Surg 152:274-282
Katz, Steven J; Janz, Nancy K; Abrahamse, Paul et al. (2017) Patient Reactions to Surgeon Recommendations About Contralateral Prophylactic Mastectomy for Treatment of Breast Cancer. JAMA Surg 152:658-664

Showing the most recent 10 out of 32 publications